Erik Tambuyzer
Director/Board Member at Augustine Therapeutics NV
Erik Tambuyzer active positions
| Companies | Position | Start | End |
|---|---|---|---|
Augustine Therapeutics NV
 Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Director/Board Member | 19/03/2021 | - |
Career history of Erik Tambuyzer
Training of Erik Tambuyzer
| Katholieke Universiteit Leuven | Doctorate Degree |
Statistics
International
| Belgium | 3 |
Operational
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Services | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Augustine Therapeutics NV
Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Health Services |
- Stock Market
- Insiders
- Erik Tambuyzer
- Experience
